Literature DB >> 15460530

Stenotrophomonas maltophilia as a nosocomial pathogen.

O Köseoğlu1, B Sener, D Gülmez, B Altun, D Gür.   

Abstract

The aim of this study was to investigate the molecular epidemiology of Stenotrophomonas maltophilia in a university hospital in Turkey. Thirty nine clinical isolates were collected from 37 patients and one from an environmental source between 1998 and 2001. Susceptibility to 11 antimicrobials was studied. The isolates were categorised into six groups: A through F. Trimethoprim sulfamethoxazole was the most active agent against the tested isolates. Genotypic analysis by pulsed-field gel electrophoresis (PFGE) of clinical isolates identified 21 different PFGE patterns. Three most common clusters were composed of 11, seven and four strains. Antimicrobial susceptibility identified multi-resistant phenotype in all S. maltophilia PFGE clones. All the remaining 18 isolates (45%) revealed unique PFGE patterns. Resistance was not lower in unique strains. The clones mainly with two unique macrorestriction profiles strongly suggests nosocomial transmission of these strains from either a common source and/or between patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15460530

Source DB:  PubMed          Journal:  New Microbiol        ISSN: 1121-7138            Impact factor:   2.479


  3 in total

1.  Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem.

Authors:  Asma Marzouq Al-Jasser
Journal:  Ann Clin Microbiol Antimicrob       Date:  2006-09-18       Impact factor: 3.944

Review 2.  Stenotrophomonas maltophilia as an Emerging Ubiquitous Pathogen: Looking Beyond Contemporary Antibiotic Therapy.

Authors:  Anthony A Adegoke; Thor A Stenström; Anthony I Okoh
Journal:  Front Microbiol       Date:  2017-11-30       Impact factor: 5.640

3.  Culture-independent analysis of bacterial diversity in a child-care facility.

Authors:  Lesley Lee; Sara Tin; Scott T Kelley
Journal:  BMC Microbiol       Date:  2007-04-05       Impact factor: 3.605

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.